Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma

Dr Ribas opened this segment by discussing the new immunotherapy agents used in the treatment of metastatic melanoma. Specifically, he discussed the agents vemurafenib (Zelboraf), dabrafenib (Taflinar), and trametinib (Mekinist).

Dr Ribas and Dr Weber agreed that the combination of dabrafenib and tramtinib will in fact be cost-effective. “It’s one of the first examples that I know of in medicine where you have 2 effective drugs and put them together and they’re not only more effective, but they’re less toxic when you use them together,” said Dr Ribas.